Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical trial NCT03848845 · COMPLETED
Trial details
- NCT number
- NCT03848845
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-14
- Primary completion
- 2021-10-18
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.